Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

LHCOX vs HRTS overlap: 49% of top holdings shared

Bottom line

How much do LHCOX and HRTS overlap?

49% of their top holdings overlap by weight. 11 securities appear in both funds' top 25, making up 40.3% of LHCOX's assets and 45.7% of HRTS's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

LHCOXHRTS
Weight overlap (top 25)49%
Shared holdings11
Weight in shared holdings40.3%45.7%
Total positions6145
Expense ratio0.68%0.75%
Holdings as ofJul 31, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Holdings LHCOX and HRTS have in common

Holding% of LHCOX% of HRTSOverlap
Eli Lilly & Co10.40%11.52%10.40%
UnitedHealth Group Inc5.39%5.24%5.24%
Johnson & Johnson4.96%3.59%3.59%
Novartis AG4.19%3.38%3.38%
Gilead Sciences Inc3.53%3.43%3.43%
Thermo Fisher Scientific Inc2.31%3.97%2.31%
Vertex Pharmaceuticals Inc2.24%2.93%2.24%
AstraZeneca PLC1.97%4.00%1.97%
Bridgebio Pharma Inc1.84%2.59%1.84%
Edwards Lifesciences Corp1.78%1.75%1.75%
Revolution Medicines Inc1.67%3.33%1.67%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in LHCOX

  1. Natera Inc — 3.60%
  2. CVS Health Corp — 3.33%
  3. Guardant Health Inc — 2.61%
  4. Galderma Group AG — 2.60%
  5. Cogent Biosciences Inc — 2.27%
  6. 10X Genomics Inc — 2.16%
  7. BeOne Medicines Ltd — 2.06%
  8. Ascendis Pharma A/S — 1.99%
  9. Madrigal Pharmaceuticals Inc — 1.91%
  10. Arrowhead Pharmaceuticals Inc — 1.52%
  11. Protagonist Therapeutics Inc — 1.44%
  12. Dianthus Therapeutics Inc — 1.44%
  13. Adaptive Biotechnologies Corp — 1.42%
  14. Illumina Inc — 1.42%

Only in HRTS

  1. Novo Nordisk A/S — 5.24%
  2. Roche Holding AG — 4.50%
  3. Merck & Co Inc — 4.27%
  4. Danaher Corp — 2.66%
  5. Abbott Laboratories — 2.61%
  6. Cytokinetics Inc — 2.52%
  7. AbbVie Inc — 2.40%
  8. Bristol-Myers Squibb Co — 2.09%
  9. Teva Pharmaceutical Industries — 2.06%
  10. Dexcom Inc — 1.92%
  11. Amgen Inc — 1.91%
  12. Medtronic PLC — 1.88%
  13. McKesson Corp — 1.71%
  14. Regeneron Pharmaceuticals Inc — 1.67%

Asset mix

Asset typeLHCOXHRTS
Stocks98.2%99.2%
Repurchase agreements1.2%—
Cash & short-term funds0.8%0.7%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Country mix

CountryLHCOXHRTS
US78.5%74.9%
CH8.8%7.9%
DK2.0%7.0%
GB2.0%4.0%
NL2.2%—
IL1.2%2.1%
IE—1.9%
BE1.4%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Check another pair

FAQ

How much do LHCOX and HRTS overlap?
About 49% by weight. 11 securities appear in both funds' top 25 holdings; they make up 40.3% of LHCOX's assets and 45.7% of HRTS's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do LHCOX and HRTS have in common?
The largest shared holdings are Eli Lilly & Co, UnitedHealth Group Inc, Johnson & Johnson, Gilead Sciences Inc, Novartis AG.
Should I own both LHCOX and HRTS?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, LHCOX or HRTS?
LHCOX is broader, with 61 positions versus 45 for HRTS. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.